Genmab A/S Announces Results of HUMAX-CD4(TM) Trial
Advertisement
Genmab A/S announced additional encouraging duration of response data from one of its HuMax-CD4 (zanolimumab) phase II studies treating patients with mycosis fungoides (MF) a type of cutaneous T-cell lymphoma (CTCL). Data from all patients in the study showed a median response duration of more than 45 weeks (10.5 months). Furthermore, analysis of the time to response showed that 85% of the responding patients (11/13) obtained clinical response within 8 weeks. Additionally, previously released data was analyzed to assess the relation between dose and the serum concentration of HuMax-CD4 measured immediately before the next treatment (trough values). Increasing doses of HuMax-CD4 resulted in increased trough values.
"This latest set of duration of response data is very encouraging and indicates that HuMax-CD4 may be effective in treating CTCL patients with mycosis fungoides, especially at higher doses," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.